Acepodia

📍 Alameda, United States🗓 Founded 2016👥 38 employees💰 Last funded Nov 2022
Biotechnology Research🌐 acepodia.com
Website LinkedIn
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Acepodia?
Acepodia has 1 investors on record on gritt.io and 1 late-stage investors.
When did Acepodia last raise funding?
The most recent investment in Acepodia recorded on gritt.io was in November 2022.
When was Acepodia founded?
Acepodia was founded in 2016.
What industry is Acepodia in?
Acepodia operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Acepodia based?
Acepodia is headquartered in Alameda, United States.